TY - JOUR
AR - ACO-2020-2-104
TI - Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) Followed by Chemoradiotherapy for Locally Advanced Head and Neck Cancer: Can It Achieve Its Potential?
AU - Nicholas P, Rowell
JO - Annals of Clinical Oncology
PY - 2020
DA - Mon 28, Sep 2020
SN - 2674-3248
DO - http://dx.doi.org/10.31487/j.ACO.2020.02.04
UR - https://www.sciencerepository.org/induction-chemotherapy-with-docetaxel-cisplatin-and-5-fluorouracil_ACO-2020-2-104 
KW - Head and neck cancer, induction chemotherapy, docetaxel, chemoradiotherapy, dose intensity
AB - Objective: In view of concerns about toxicity and deliverability of induction chemotherapy and its impact
on subsequent chemoradiotherapy, a retrospective review was carried out with patients treated for locally
advanced head and neck cancer (LAHNC) in a single centre between 2007-2017.
Patients and Interventions: Patients with LAHNC and good performance status receiving induction
chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) followed by chemoradiotherapy to 70Gy
in 35 daily fractions with platinum-based chemotherapy.
Main Outcome Measures: Overall and cause-specific survival, rates of locoregional recurrence or distant
metastasis, treatment-related toxicity.
Results: One hundred and eight patients with LAHNC were treated with 1-4 cycles of TPF (95 receiving
two cycles) followed by chemoradiotherapy. The mean delivered dose intensity was 97.6% for all TPF
cycles. Median interval from the start of the final cycle of TPF to the start of radiotherapy was 24 days, with
92/103 (89%) starting radiotherapy within 28 days. Median radiation treatment time was 47 days. The mean
delivered dose intensity for chemotherapy delivered concurrently with radiotherapy was 97%. There were
significantly fewer dose reductions in those receiving platinum/5FU combinations than platinum only
regimes (P < 0.0001). For those receiving two cycles of TPF, 90% of patients completed the whole course
of treatment within 14 weeks (median overall treatment time 13.1 weeks). There were four treatment-related
deaths during induction chemotherapy and none during radiotherapy. Twenty-five developed locoregional
failure and 13 distant metastases (both in eight). Actuarial overall survival was 60.7% at five years, with
progression-free survival of 77.9% at two years and 74.1% at five years. For oropharynx cancers, overall
survival was 70.4% and progression-free survival 80.8% at five years.
Conclusion: Although significant toxicity from TPF was observed, with appropriate support, it is possible
to complete treatment without undue compromise of subsequent treatment.